Results 191 to 200 of about 8,310 (206)
Some of the next articles are maybe not open access.
Management of Medication-Related Osteonecrosis of the Jaw
Oral and Maxillofacial Surgery Clinics of North America, 2015Medication-related osteonecrosis of the jaw (MRONJ) primarily involves patients receiving intravenous bisphosphonates for treatment of skeletal-related malignancies, oral bisphosphonates, and denosumab. There is no consensus regarding the clinical management of MRONJ.
William Bradford, Williams +1 more
openaire +2 more sources
Medication-Related Osteonecrosis of the Jaws
2021Medication-related osteonecrosis of the jaw is an area of exposed bone in the maxilla or mandible that does not heal over a period of 6–8 weeks. It is a well-known side effect of bisphosphonate therapy, first described by Marx in 2003. More recently, other drugs have been incriminated: monoclonal antibodies inhibiting osteoclastic activity, such as ...
Leonor Costa Mendes, Bruno Courtois
openaire +1 more source
Medication-related osteonecrosis of the jaw: the radiologist’s role
Radiología (English Edition), 2023In recent decades, the dreaded adverse effect of bisphosphonates, osteonecrosis of the jaw, has been widely reported and described in detail. Osteonecrosis of the jaw consists of the destruction of part of the maxilla as a consequence of these antiresorptive drugs.
R, Alemán Millares +3 more
openaire +2 more sources
Medication-Related Osteonecrosis of the Jaw
New England Journal of Medicine, 2023Yu-Feng Chen, Hong-Po Chang
+5 more sources
Interventions for managing medication-related osteonecrosis of the jaw
Cochrane Database of Systematic Reviews, 2022Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction experienced by some individuals to certain medicines commonly used in the treatment of cancer and osteoporosis (e.g. bisphosphonates, denosumab, and antiangiogenic agents), and involves the progressive destruction of bone in the mandible or maxilla.
Natalie H, Beth-Tasdogan +4 more
openaire +2 more sources
Infection and Medication-related Osteonecrosis of the Jaw
Journal of Dental Research, 2015Medication-related osteonecrosis of the jaw (MRONJ), although initially believed to be exclusively associated with bisphosphonates, has been implicated in recent reports with additional drugs, especially the bone antiresorptive denosumab. The pathophysiology has not been fully elucidated, and no causal association between bone antiresorptive regimens ...
H, Katsarelis +3 more
openaire +2 more sources
Medication-Related Osteonecrosis of the Jaw
2022Journal of The Dental Association of Thailand, 72, 2, 204 ...
openaire +1 more source
Pain characteristics in medication-related osteonecrosis of the jaws
Supportive Care in Cancer, 2020To characterise pain from medication-related osteonecrosis of the jaws (MRONJ) and the effects of antimicrobial treatment on it.Data from files of patients diagnosed with MRONJ according to the position paper of the American Association of Oral and Maxillofacial Surgeons (2014) and Multinational Association of Supportive Care in Cancer and American ...
Yaron, Haviv +5 more
openaire +2 more sources
Medication-related osteonecrosis of the jaw: An institution’s experience
CRANIO®, 2018This study aimed to evaluate and report the outcomes associated with the management of patients who were treated surgically for medication-related osteonecrosis of the jaw (MRONJ).Methods: Demographic and medical profiles of patients with a diagnosis of MRONJ were created.
Mehmet Ali Altay +6 more
openaire +2 more sources
Bacterial diversity in medication-related osteonecrosis of the jaw
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2017The aim was to study the association between microflora and medication-related osteonecrosis of the jaw (MRONJ) by using culture-independent molecular techniques to detect bacteria in necrotic bone lesions.Included were 18 consecutive patients with MRONJ, 10 with osteoporosis and 8 cancer patients.
Fredrik, Hallmer +5 more
openaire +2 more sources